Used in immunotherapy for cancer treatment, this antibody targets the OX40 receptor to enhance T-cell activation and immune response against tumors. It is being investigated in clinical trials for solid tumors and hematologic malignancies, aiming to boost anti-tumor immunity by promoting T-cell survival, proliferation, and cytokine production. Its mechanism supports potential combination with other immunotherapies like checkpoint inhibitors to improve treatment outcomes.